logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
Showing 1 - 20 of 39 Items
Showing 1 - 20 of 39 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Short Report

Providing emergency medical care at the Belarus-Poland border

Zadykowicz R, Kuc J, Ladomirska J, Zamatto F, Lim SY
2025-05-01 • Forced Migration Review
2025-05-01 • Forced Migration Review
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Slide Presentation
Journal Article
|
Review
Journal Article
|
Research
Conference Material
|
Slide Presentation
Conference Material
|
Video

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial (PRACTECAL-PRO): a mixed-methods, multi-site study

Stringer B
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Slide Presentation
Conference Material
|
Poster
Conference Material
|
Abstract
Conference Material
|
Video

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Yatskevich N
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Abstract
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Short Report
Research & Publication Resources
|
Research Protocol
Conference Material
|
Video

24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial

Berry C, Motta I, Kazounis E, Fielding K, Dodd M,  et al.
2022-06-07 • MSF Scientific Days International 2022

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A,  et al.
2025-02-18 • Clinical Infectious Diseases
2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M,  et al.
2025-02-01 • Lancet Global Health
2025-02-01 • Lancet Global Health

BACKGROUND

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...

Supporting multidrug-resistant or rifampicin-resistant TB treatment adherence in people with harmful use of alcohol through person-centred care

Harrison RE, Shyleika V, Vishneuski R, Leonovich O, Vetushko D,  et al.
2024-11-06 • Oxford Medical Journal
2024-11-06 • Oxford Medical Journal

BACKGROUND

TB is concentrated in populations with complex health and social issues, including alcohol use disorders (AUD). We describe treatment adherence and o...

How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M,  et al.
2024-06-06 • Antimicrobial Agents and Chemotherapy
2024-06-06 • Antimicrobial Agents and Chemotherapy
Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we inves...

Application of the Médecins Sans Frontières clinical trial transparency policy: cost analysis of TB-PRACTECAL, a multicentre phase 2–3 trial in drug-resistant tuberculosis

Gotham D, Martin M, Barber M, Kazounis E, Batts C,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024

The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: An individual patient data meta-analysis

Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C,  et al.
2024-03-20 • Clinical Infectious Diseases
2024-03-20 • Clinical Infectious Diseases
BACKGROUND
Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include ...

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N,  et al.
2024-02-01 • Lancet Respiratory Medicine
2024-02-01 • Lancet Respiratory Medicine
BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Yatskevich N, Hurevich H, Solodovnikova V, Garsevanidze E, Lachenal N,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial (PRACTECAL-PRO): a mixed-methods, multi-site study

Stringer B, Lowton K, Cusinato M, Fielding K, Liverko I,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023

ECG findings in BPaL-based TB treatment regimens: the geographical effect on QT prolongation

Motta I, Cusinato M, Ludman A, Abdrasuliev T, Butabekov I,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial: PRACTECAL-PRO

Stringer B, Lowton K, Cusinato M, Fielding K, Liverko I,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The TB-PRACTECAL study trialed a shorter, more tolerable regimen of oral drugs than standard of care (SoC) – which can last for up to 20 months and involve both injectab...

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Yatskevich N, Hurevich H, Solodovnikova V, Garsevanidze E, Lachenal N,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The total duration of treatment for rifampicin-resistant tuberculosis (RR-TB) in Belarus prior to December 2022 was 18-20 months. The efficacy of treatment with such reg...

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...

A 24-week, all-oral regimen for rifampin-resistant tuberculosis

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N,  et al.
2022-12-22 • New England Journal of Medicine
2022-12-22 • New England Journal of Medicine
BACKGROUND
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S,  et al.
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy

Sweeney S, Gomez G, Kitson N, Sinha A, Yatskevich N,  et al.
2020-10-10 • BMJ Open
2020-10-10 • BMJ Open
INTRODUCTION
Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are...
2022-06-07 • MSF Scientific Days International 2022
No abstract available.